FDA sends warning letters to Amazon, three OTC drugmakers, and a drug compounder
Regulatory NewsJoanne S. Eglovitch
APIsComplianceCompoundingGMPManufacturingPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyUnited StatesWarning letters